Strategic Management Of The Mature Product Portfolio

Outsourcing has long been seen as a strategy for pharmaceutical companies to access specialized expertise and cut costs in complex regulatory environments. Today, a wide array of processes, from early clinical development to manufacturing, are outsourced. While big pharma has made progress, with 40-45% of work outsourced, there's untapped potential, especially in managing established products.

This area offers significant benefits amid revenue pressures and cost constraints. Managing established product portfolios across regions demands innovative approaches to ensure compliance and minimize risks. These challenges call for a new outsourcing paradigm that integrates expertise, regulatory knowledge, efficiency, and cost containment, moving beyond traditional low-cost offshore staffing models.

The emerging outsourcing paradigm, dubbed the second wave, relies on a customized blend of in-country, near-shore, and offshore resources. This ensures seamless integration of partner domain experts into the pharmaceutical company's structure, with centralized portfolio oversight. These models hinge on expertise, knowledge, and innovation, leading to long-term cost reduction and efficiency gains. By adopting this approach, pharma companies can concentrate on core activities and strategic decision-making, rather than tactical tasks and internal technical infrastructure. Let's embrace this new paradigm to unlock its full potential and drive industry-wide advancement.